Estrogen and C-reactive protein: Does an alternate route lead to a more attractive destination?

Thrombosis and Haemostasis

Volumn 90, Issue 1, 2003, Pages 1-2

  Duvernoy, Claire ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 7; C REACTIVE PROTEIN; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; ESTROGEN RECEPTOR; FIBRINOPEPTIDE A; GESTAGEN; HORMONE; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; PLACEBO; PROGESTERONE; PROTHROMBIN; RETINOIC ACID DERIVATIVE; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA;

AGING; ATHEROSCLEROSIS; BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFECT; DRUG TOLERABILITY; EDITORIAL; EVIDENCE BASED MEDICINE; HEART INFARCTION; HORMONE ACTION; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; MENOPAUSAL SYNDROME; MOOD DISORDER; OUTCOMES RESEARCH; PATHOGENESIS; POSTMENOPAUSE; PRACTICE GUIDELINE; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RECEPTOR INTRINSIC ACTIVITY; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; SECONDARY PREVENTION; THROMBOSIS; VAGINAL DRYNESS;

EID: 0037962021     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613591     Document Type: Editorial

References (9)

1. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-13.
2. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
3. Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002; 53: 605-19.
4. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-65.
5. Lacut K, Oger E, Le Gal G, et al. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on c-reactive protein. Thromb Haemost 2003; 90: 124-31.
6. Decensi A, Omodei U, Robertson C, et al. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation 2002; 106: 1224-8.
7. Vongpatanasin W, Tuncel M, Wang Z, et al. Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Amer Coll Cardiol 2003; 41: 1358-63.
8. Cherry N, Gilmour K, Hannaford P, et al. Oestrogen therapy for prevention of reinfarction in postmenopausal women: A randomised placebo controlled trial. Lancet 2002; 360: 2001-8.
9. Clarke SC, Kelleher J, Lloyd-Jones H, et al. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: The Papworth HRT atherosclerosis study. BJOG 2002; 109: 1056-62.